e-Drug3D

1416

cas 1716-12-7

CLASS

METABOLISM
SUPPLEMENT
DECREASED ELEVATED PLASMA AMMONIA GLUTAMINE LEVELS
ANTIHYPERAMMONEMIC
UREA CYCLE DISORDERS
RAPIDLY METABOLIZED TO PHENYLACETATE
NITROGEN-BINDING AGENT FOR CHRONIC UREAC CYCLE DISORDERS (UCDS)

ROUTE (list)

ORAL

PK parameters

Tmax 1 HOUR
Cmax 1.32 MILLIMOLAR (5 GRAMS)
PPB 89 PERCENT
t1/2 0.77 HOUR

TARGET PHENYLACETYL-COA: L-GLUTAMINE-N-ACETYLTRANSFERASE

PDB
3TZ2 (CRYSTAL STRUCTURE OF BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE, PHENYLBUTYRATE COMPLEX)

Ligand code = CLT (link to the list of PDB complexes)

Download experimental 3D coordinates of CLT with added hydrogens

MW 163.19
NB_atoms 12
XLogP 0.76
PSA 35.61
NB_HD 0
NB_HA 2
fsp3 0.30
Lipinski(0=no;1=yes) 1

FDA
NDA 020572 (label) INN (SODIUM PHENYLBUTYRATE) BUPHENYL (HORIZON THERAP US) APPROVAL= AP YEAR= 1996 DISCONTINUED
NDA 020573 (label) INN (SODIUM PHENYLBUTYRATE) BUPHENYL (HORIZON THERAP US) APPROVAL= AP YEAR= 1996 DISCONTINUED
NDA 090910 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (ALVOGEN) APPROVAL= AP YEAR= 2011 DISCONTINUED
NDA 202819 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (SIGMAPHARM LABS LLC) APPROVAL= AP YEAR= 2013 DISCONTINUED
NDA 203918 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (PH HEALTH) APPROVAL= AP YEAR= 2016
NDA 204395 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (PH HEALTH) APPROVAL= AP YEAR= 2016
NDA 216513 (label) INN (SODIUM PHENYLBUTYRATE) PHEBURANE (MEDUNIK) APPROVAL= AP YEAR= 2022
NDA 214860 (label) INN (SODIUM PHENYLBUTYRATE) OLPRUVA (ACER) APPROVAL= AP YEAR= 2022
NDA 216462 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (GLENMARK PHARMS LTD) APPROVAL= AP YEAR= 2022
NDA 216660 (label) INN (SODIUM PHENYLBUTYRATE ; TAURURSODIOL) RELYVRIO (AMYLYX) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY DISCONTINUED
NDA 220418 (pdf not found) INN (SODIUM PHENYLBUTYRATE) SODIUM PHENYLBUTYRATE (NAVINTA LLC) APPROVAL= AP YEAR= 2026

e-Drug3D

1604

cas 611168-24-2

CLASS

NITROGEN-BINDING AGENT FOR CHRONIC UREAC CYCLE DISORDERS (UCDS)
AMMONIA SCAVENGER
SUBSTRATE METABOLIZED BY LIPASES (PANCREATIC TRIGLYCERIDE LIPASE, CARBOXYL ESTER LIPASE, AND PANCREATIC LIPASE–RELATED PROTEIN 2) AND BY ESTERASES IN HUMAN PLASMA (IN VITRO)

ROUTE (list)

ORAL

PK parameters

MW 530.63
NB_atoms 39
XLogP 6.05
PSA 74.669
NB_HD 0
NB_HA 6
fsp3 0.36
Lipinski(0=no;1=yes) 0

FDA
NDA 203284 (label) INN (GLYCEROL PHENYLBUTYRATE) RAVICTI (HORIZON THERAP US) APPROVAL= AP YEAR= 2013
NDA 205742 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (PH HEALTH) APPROVAL= AP YEAR= 2021
NDA 215139 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (ANNORA PHARMA) APPROVAL= TA YEAR= 2022
NDA 207694 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (LUPIN) APPROVAL= AP YEAR= 2026
NDA 218738 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (TEVA PHARMS INC) APPROVAL= AP YEAR= 2026
NDA 219540 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (MSN) APPROVAL= AP YEAR= 2026
NDA 220313 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (AUROBINDO PHARMA) APPROVAL= AP YEAR= 2026
NDA 220568 (pdf not found) INN (GLYCEROL PHENYLBUTYRATE) GLYCEROL PHENYLBUTYRATE (NAVINTA LLC) APPROVAL= AP YEAR= 2026